This is an old revision of the document!
Bristol-Myers Squibb
Bristol-Myers Squibb holds the exclusive license to develop, manufacture and commercialize the monoclonal antibody treatment owned by Rockefeller University.1)
The company is also part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics”.2)
1)
Bristol-Myers Squibb. (2021, September 7). COVID-19 Updates. Retrieved December 6, 2021, from
https://www.bms.com/about-us/responsibility/coronavirus-updates.html
2)
Our Research Efforts. (2021, September 7). Bristol-Myers Squibb. https://www.bms.com/about-us/responsibility/coronavirus-updates/our-research-efforts.html